^
    Back
    Association details:
    Biomarker:RET L629P
    Cancer:Head and Neck Cancer
    Drug:Zolinza (vorinostat) (HDAC inhibitor) +
    ABT-737 (Bcl2 antagonist)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Cancer Discov
    Title:

    Mcl-1 and FBW7 control a dominant survival pathway underlying HDAC and Bcl-2 inhibitor synergy in squamous cell carcinoma

    Excerpt:
    Moreover, somatic FBW7 mutation in SCC is associated with stabilized Mcl-1 and high Bim levels, resulting in a poor response to standard chemotherapy but a robust response to HDAC inhibitors and enhanced synergy with the combination vorinostat/ABT-737.
    DOI:
    10.1158/2159-8290.CD-12-0417